NFE2L2 and Alzheimer disease: In contrast, studies performed on another transgenic model of AD carrying a homozygous PSEN1M146V knock-in mutation and homozygous mutant transgenes for Swedish APPKM670/671NL and MAPTP301L (3xTg-AD mice) have not observed differences in the levels of Nfe2l2 or its signaling pathway [189].